Scilex (SCLX) Expected to Announce Earnings on Monday

Scilex (NASDAQ:SCLX) is expected to be issuing its quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $17.79 million for the quarter.

Scilex Stock Performance

NASDAQ:SCLX opened at $4.01 on Friday. Scilex has a 52-week low of $3.60 and a 52-week high of $80.50. The company has a market cap of $27.88 million, a price-to-earnings ratio of -4.83 and a beta of 1.10. The firm’s 50-day moving average is $7.82 and its 200-day moving average is $14.92.

Analysts Set New Price Targets

A number of research analysts have commented on SCLX shares. D. Boral Capital restated a “hold” rating on shares of Scilex in a research note on Friday, April 11th. D Boral Capital downgraded Scilex from a “strong-buy” rating to a “hold” rating in a report on Friday, April 11th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $455.00.

About Scilex

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.